## Jan Snoeys

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8818272/publications.pdf

Version: 2024-02-01

471509 552781 1,724 26 17 26 h-index citations g-index papers 27 27 27 2802 docs citations times ranked citing authors all docs

| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Insight into the Colonic Disposition of Sulindac in Humans. Journal of Pharmaceutical Sciences, 2021, 110, 259-267.   | 3.3  | 9         |
| 2  | Physiologicallyâ€Based Pharmacokinetic Models for Evaluating Membrane Transporter<br>MediatedÂDrug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and<br>Recommendations. Clinical Pharmacology and Therapeutics, 2020, 107, 1082-1115. | 4.7  | 88        |
| 3  | Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nature Reviews Drug Discovery, 2020, 19, 131-148.   | 46.4 | 153       |
| 4  | The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine. Toxicology and Applied Pharmacology, 2020, 403, 115163.                                  | 2.8  | 8         |
| 5  | Amino acid levels determine metabolism and CYP450 function of hepatocytes and hepatoma cell lines. Nature Communications, 2020, 11, 1393.   | 12.8 | 79        |
| 6  | Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation. Npj Biofilms and Microbiomes, 2020, 6, 9.  | 6.4  | 24        |
| 7  | Insight into the colonic disposition of celecoxib in humans. European Journal of Pharmaceutical Sciences, 2020, 145, 105242.  | 4.0  | 12        |
| 8  | High-throughput confocal imaging of differentiated 3D liver-like spheroid cellular stress response reporters for identification of drug-induced liver injury liability. Archives of Toxicology, 2019, 93, 2895-2911.  | 4.2  | 40        |
| 9  | Acute Metabolic Switch Assay Using Glucose/Galactose Medium in HepaRG Cells to Detect<br>Mitochondrial Toxicity. Current Protocols in Toxicology / Editorial Board, Mahin D Maines<br>(editor-in-chief) [et Al ], 2019, 80, e76.                                      | 1.1  | 12        |
| 10 | Development of an LC–MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1073, 80-89.       | 2.3  | 12        |
| 11 | Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study. Toxicological Sciences, 2018, 162, 655-666.   | 3.1  | 219       |
| 12 | Effect of Plasma Protein Binding on the Anti-Hepatitis B Virus Activity and Pharmacokinetic Properties of NVR 3-778. Antimicrobial Agents and Chemotherapy, 2018, 62, .   | 3.2  | 3         |
| 13 | Advancing Predictions of Tissue and Intracellular Drug Concentrations Using <i>InÂVitro</i> , Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clinical Pharmacology and Therapeutics, 2018, 104, 865-889.                                      | 4.7  | 92        |
| 14 | The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity. Toxicology in Vitro, 2018, 53, 136-147.  | 2.4  | 33        |
| 15 | Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics, 2017, 56, 781-792.   | 3.5  | 8         |
| 16 | Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 767-782.   | 3.3  | 30        |
| 17 | In Vitro Model for Hepatotoxicity Studies Based on Primary Human Hepatocyte Cultivation in a<br>Perfused 3D Bioreactor System. International Journal of Molecular Sciences, 2016, 17, 584.  | 4.1  | 19        |
| 18 | Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Scientific Reports, 2016, 6, 25187.   | 3.3  | 502       |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man. Journal of Pharmaceutical Sciences, 2016, 105, 2974-2981.  | 3.3 | 36        |
| 20 | In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. Drug Metabolism and Disposition, 2016, 44, 1682-1691.   | 3.3 | 18        |
| 21 | A physiologically based pharmacokinetic modeling approach to predict drug–drug interactions between domperidone and inhibitors of CYP3A4. Biopharmaceutics and Drug Disposition, 2016, 37, 15-27.   | 1.9 | 10        |
| 22 | Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Archives of Toxicology, 2016, 90, 2979-3003.   | 4.2 | 50        |
| 23 | Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clinical Pharmacokinetics, 2016, 55, 197-208.   | 3.5 | 65        |
| 24 | Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 1-7. | 4.3 | 62        |
| 25 | The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death.<br>Toxicology in Vitro, 2015, 29, 732-740.  | 2.4 | 135       |
| 26 | Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of <i>In Vitro</i> Models. Applied in Vitro Toxicology, 2015, 1, 175-186.  | 1.1 | 5         |